Biotech & Pharma · Week of Nov 9, 2026
Eli Lilly and Company brings obesity data to ObesityWeek: biotech week
Immunic, Abeona, Curis, Trevi, Protalix, Castle and Viridian posted Q3 results and trial data, with many readouts set for December 2026 through 2028.
Eli Lilly and Company led the week with a slate of ObesityWeek 2026 presentations spanning Zepbound, Foundayo, EloraTZP, eloralintide and retatrutide, including Phase 2 and Phase 3 data on weight loss, sleep apnea and knee osteoarthritis pain. Conference data also came from Protalix BioTherapeutics at ACR Convergence 2026 and Castle Biosciences at SDPA and Dermato-Onco2026, while Viridian Therapeutics reported Phase 1 results for its FcRn inhibitor VRDN-008.
Third-quarter reports from Immunic, Abeona Therapeutics, Curis and Trevi Therapeutics centered on cash runway and upcoming catalysts. Runways ranged from the first quarter of 2027 at Curis to 2030 at Trevi. Immunic and Curis both expect data in December 2026. Abeona and Curis each disclosed private placements, and Abeona paired its financing with an asset acquisition.


Immunic, Inc.
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Immunic reported a third-quarter 2026 net loss of approximately $42.3 million and cash of $132.0 million, which it expects to fund operations into late 2027. Top-line data from the Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS are expected in December 2026, and the company plans a U.S. NDA submission in mid-2027 if results are positive.
Abeona Therapeutics Inc.
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
Abeona reported third-quarter net ZEVASKYN revenue of $13.5 million, up 18% from the second quarter, with fifteen patient treatments completed since launch and NTAP status effective October 1, 2026. The company also acquired Phase 3-ready ABO-801 for eosinophilic esophagitis from Ellodi Pharmaceuticals for $20 million in common stock plus milestones and royalties, and entered into a $30 million private placement.

Curis, Inc.
Curis Provides Third Quarter 2026 Business Update
Curis reported a third-quarter 2026 net loss of $8.1 million and no revenue, following the sale of Erivedge royalties to Oberland. The company says its $5.0 million in cash, plus approximately $7.5 million in net proceeds from the October 2026 Private Placement, should fund operations into the first quarter of 2027, and it expects initial TakeAim CLL data in December 2026.
Trevi Therapeutics, Inc.
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Trevi reported a third-quarter 2026 net loss of $21.5 million and $299.4 million in cash, cash equivalents and marketable securities, which it expects to provide runway into 2030. The company plans to start a Phase 2 trial of about 120 patients in non-IPF ILD-related chronic cough in the first quarter of 2027, subject to FDA protocol review, and expects topline Phase 3 OCEAN-2 results in the second half of 2027.

Protalix BioTherapeutics, Inc.
Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
Protalix says that at 36 mg, mean plasma uric acid stayed below the 6.0 mg/dL target for up to 12 weeks after a single infusion of PRX-115, in higher-dose cohorts of its Phase 1 single ascending dose study presented at ACR Convergence 2026. Previously reported safety data included one anaphylactic reaction that resolved, and top-line Phase 2 RELEASE results are expected in the second half of 2027.

Castle Biosciences, Inc.
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
Castle Biosciences will present DecisionDx-Melanoma data showing five-year recurrence-free survival of 92.5% for low-risk i31-ROR results versus 54.2% for high-risk results in 1,726 stage I–III patients. The company says the algorithm predicted five-year recurrence more accurately than AJCC staging, and it also reported data in thin T1a melanomas.
Viridian Therapeutics, Inc.\DE
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
Viridian reported Phase 1 results for subcutaneous FcRn inhibitor VRDN-008 in healthy volunteers, citing a half-life of 15–18 days, a 74% IgG reduction at peak, and no serious adverse events or dose-limiting toxicities. The company plans a registrational trial in myasthenia gravis in mid-2027, pending regulatory feedback, testing Q4W and Q8W dosing.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not The Digest Lab reporting.